The clinical roles of sPD-1 and sPD-L1 as biomarkers and/or therapeutic targets are nowadays widely investigated in cancer research, while an emerging number of studies explore the possible roles of these proteins in the development and course of autoimmune diseases like SLE or rheumatoid arthritis [10,11,12,13]. Here, HOXD13 is linked to systemic lupus erythematosus.